期刊文献+

能谱CT在肺癌淋巴结转移诊断中的临床应用价值研究 被引量:1

Energy Spectrum CT Clinical Application Value in The Diagnosis of Lung Cancer Lymph Node Metastasis
下载PDF
导出
摘要 目的:研究能谱CT诊断肺癌淋巴结转移的临床价值。方法:选取我院2016年5月至2017年4月行能谱CT检查并经病理证实的中央型小细胞肺癌伴纵隔淋巴结肿大患者35例、肺鳞癌伴纵隔或肺门淋巴结肿大患者20例,通过CT值、碘含量、有效原子序数等参数的对比,分析能谱CT的诊断情况。结果:小细胞肺癌组和转移性淋巴结组的CT值差别不大(P>0.05),其与反应增生性淋巴结组的CT值有较大差别(P<0.05);反应增生性淋巴结组有效原子序数、碘含量高于其他两组(P<0.05);碘含量、有效原子序数的阳性及阴性预测值无明显差别,转移性淋巴结诊断的准确率为85.7%,反应增生性淋巴结诊断的准确率为68.6%。结论:能谱CT可为肺癌淋巴结转移的诊断与鉴别诊断提供依据,具有较高的临床应用价值。 Objective:to study the energy spectrum the clinical value of CT in the diagnosis of lung cancer lymph node metastasis.Methods:from May 2016 to April 2016 line spectrum confirmed by pathology and CT examination of central type of 35 patients with small cell lung cancer with mediastinal lymph node enlargement,pulmonary squamous carcinoma patients with mediastinal or hilum lymph node enlargement with 20 cases,by CT value,iodine,effective atomic number of parameters,such as contrast,analysis of energy spectrum CT diagnosis.Results:small cell lung cancer and metastatic lymph node groups of CT value difference( P〉0.05),with the reaction of hyperplastic lymph node groups CT value has great difference( P〈0.05); reaction hyperplastic lymph node set of effective atomic number,iodine content is higher than the other two groups( P〈0.05); Iodine content,effective atomic number of positive and negative predictive value has no obvious difference,the correct rate of diagnosing metastatic lymph nodes was 85.7%,the reaction hyperplastic lymph node diagnostic accuracy was 68.6%.Conclusion:the energy spectrum CT for the diagnosis and differential diagnosis of lymph node metastasis of lung cancer,has high clinical value.
作者 王福南 朱柳红 郭岗 Wang Funan, Zhu Liuhong, Guo Gang(Radiology Department of Xiamen No. 2 Hospital, Xiamen, Fujian 36210)
出处 《现代医用影像学》 2017年第6期1547-1550,共4页 Modern Medical Imageology
关键词 肺癌 淋巴结转移 能谱成像 Lung Cancer Lymph Node Metastasis Spectral Imaging
  • 相关文献

参考文献7

二级参考文献88

  • 1于丽娟,锻玉,梁秀艳,王欣.^(18)F-FDG PET/CT显像在肺癌诊断及探查转移灶中的价值[J].中国医学影像技术,2007,23(4):605-607. 被引量:23
  • 2刘兰平,于金明,郭洪波,付政,韩安勤,杨国仁.^(18)F-FDG PET-CT确定非小细胞肺癌淋巴结放疗靶区的初步探讨[J].中华肿瘤杂志,2007,29(6):453-456. 被引量:12
  • 3杨文锋,付政,于金明,王绍平,房玉芳,袁方,穆殿斌.^(18)F-FDG PET/CT对非小细胞肺癌区域淋巴结诊断的假阴性与假阳性研究[J].中华核医学杂志,2007,27(3):139-142. 被引量:12
  • 4Valerie WR, Hisao A, Hirokazu W, et al. The IASLC lung cancer staging project. J Thoraci Oncol, 2009, 4(5): 568-577.
  • 5Cuaron J, Dunphy M, Rimner A. Role of FDG-PET scans in staging, response assessment, and follow-up care for non-small cell lung cancer. Front Oncol, 2012, 2(2): 208.
  • 6Ose N, Sawabata Noriyoshi, Minami M, et al. Lymph node metastasis diagnosis using positron emission tomography with 2-[18F] fluoro-2-deoxy-D-glucose as a tracer and computed tomography in surgical cases of non-small cell lung cancer. Eur J Cardiothorac Surg, 2012, 42(1): 89-92.
  • 7Kligerman S, Digumarthy S. Staging of non-small cell lung cancer using integrated PET/CT. Am J Roentgenol, 2009, 193(5): 1203-1211.
  • 8Gregory DL, Hicks R J, Hogg A, et al. Effect of PET/CT on management of patients with non-small cell lung cancer: results of a prospective study with 5-year survival data. J Nucl Med, 2012, 53(7): 1007-1015.
  • 9Ford EC, Herman J, Yorke E, et al. 18F-FDG PET/CT for image-guided and intensity-modulated radiotherapy. J Nucl Med, 2009, 50(10): 1655-1665.
  • 10Fischer BM, Mortensen J, Hansen H, et al. Multimodality approach to mediastinal staging in non-small cell lung cancer. Faults and benefits of PET-CT: a randomised trial. Thorax, 2011, 66(4): 294-300.

共引文献99

同被引文献7

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部